All In Biotech

Drug Trial Radar · NCT05768997

High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Prospective, Multicenter, Randomized Phase 3 Trial of High Dose IV Iron in Combination of Erythrocytosis Stimulating Agents in Chemotherapy Induced Anemia With Functional Iron Deficiency

Last checked: Nov 20, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

312

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Hallym University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, prospective, randomized phase 3 clinical study comparing the efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone) in CIA patients with functional iron deficiency.

Conditions

  • Anemia

Interventions

  • Ferric Derisomaltose InjectionDrug

    Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes

  • Darbepoetin Alfa InjectionDrug

    Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hb changeTime frame: from baseline to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hallym University Medical Center

    Anyang-si, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.